Related Experiment Video

Updated: Jun 9, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Role of structural MRI in Alzheimer's disease

Prashanthi Vemuri1, Clifford R Jack

  • 1Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. vemuri.prashanthi@mayo.edu.

Alzheimer'S Research & Therapy
|September 3, 2010
PubMed

Insights

Structural MRI (sMRI) effectively measures brain atrophy, indicating Alzheimer's disease (AD) progression. This review covers sMRI methods, its biomarker roles, and comparisons with other AD diagnostic tools.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarker Research

Background:

  • Alzheimer's disease (AD) is characterized by neurodegeneration.
  • Brain atrophy on structural magnetic resonance imaging (sMRI) is a key indicator of AD pathology stage and severity.

Purpose of the Study:

  • To review the utility of sMRI as a biomarker for Alzheimer's disease.
  • To summarize methods for extracting information from sMRI.
  • To compare sMRI with other AD biomarkers.

Main Methods:

  • Literature review of studies utilizing sMRI for Alzheimer's disease assessment.
  • Analysis of common image processing techniques for sMRI data.
  • Comparative evaluation of sMRI against other established AD biomarkers.

Main Results:

  • sMRI provides quantitative measures of brain atrophy.
  • Various methods exist to extract meaningful data from sMRI scans.
  • sMRI plays diverse roles in diagnosing and staging AD.
  • sMRI shows promise when compared to other biomarkers.

Conclusions:

  • Structural MRI is a valuable tool for assessing neurodegeneration in Alzheimer's disease.
  • Understanding sMRI analysis methods enhances its clinical application.
  • sMRI offers complementary information to other AD diagnostic markers.

More Related Videos

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...